MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN)

Historical Holders from Q1 2014 to Q4 2025

Type / Class: Equity / Common Stock, par value $0.01 per share
Symbol: MYGN on Nasdaq
Shares outstanding: 93,104,451
Price per share: $6.15
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 88,546,250
Total reported value: $640,111,586
% of total 13F portfolios: 0%
Share change: -120,324
Value change: +$7,175,915
Avg buy value change: +0%
Avg sell value change: -0%
Number of holders: 214
Price from insider filings: $6.15

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BlackRock, Inc.	15%		$56,843,186		14,105,009		BlackRock, Inc.	30 Jun 2025
VANGUARD GROUP INC	8.5%	-16%	$56,990,583	-$9,941,091	7,882,515	-15%	The Vanguard Group	30 Sep 2025
INTEGRATED CORE STRATEGIES (US) LLC	5.1%	-4%	$34,330,404	-$1,275,278	4,748,327	-3.6%	Millennium Management LLC	30 Sep 2025
BARCLAYS PLC	4.2%	-22%	$28,480,691	-$6,945,955	3,939,238	-20%	Barclays PLC	30 Sep 2025
Camber Capital Management LP	3.4%		$26,195,000		3,100,000		Camber Capital Management LP	31 Dec 2024
DISCIPLINED GROWTH INVESTORS INC /MN	0.8%	-86%	$4,538,815	-$21,304,900	753,956	-82%	DISCIPLINED GROWTH INVESTORS INC /MN	30 Jun 2025

As of 30 Sep 2025, MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 214 institutional shareholders filing 13F forms. They hold 88,546,250 shares of 93,104,451 outstanding shares (95%) .

Top 25 institutional shareholders own 75% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
BlackRock, Inc.	16%	14,879,427	-1.3%	0%	$107,578,257
VANGUARD GROUP INC	8.5%	7,882,515	-15%	0%	$56,990,583
STATE STREET CORP	5.3%	4,976,492	+3.5%	0%	$35,980,037
MILLENNIUM MANAGEMENT LLC	5.1%	4,748,327	-3.6%	0.03%	$34,330,404
GLENVIEW CAPITAL MANAGEMENT, LLC	4.9%	4,587,407	0%	0.81%	$33,166,953
D. E. Shaw & Co., Inc.	4.9%	4,559,136	+1.1%	0.03%	$32,962,553
MORGAN STANLEY	3.9%	3,616,925	-21%	0%	$26,150,371
JACOBS LEVY EQUITY MANAGEMENT, INC	2.6%	2,442,912	+157%	0.07%	$17,662,254
GEODE CAPITAL MANAGEMENT, LLC	2.4%	2,225,169	+0.1%	0%	$16,090,499
GOLDMAN SACHS GROUP INC	2.3%	2,151,779	+68%	0%	$15,557,363
DIMENSIONAL FUND ADVISORS LP	1.8%	1,695,896	-18%	0%	$12,261,265
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	1.8%	1,678,900	+26%	0%	$12,138,447
AQR CAPITAL MANAGEMENT LLC	1.7%	1,596,826	+51%	0.01%	$11,545,052
Assenagon Asset Management S.A.	1.4%	1,304,163	+301%	0.01%	$9,429,098
Fisher Asset Management, LLC	1.4%	1,278,927	-1.2%	0%	$9,246,641
Connor, Clark & Lunn Investment Management Ltd.	1.4%	1,276,738	-8%	0.03%	$9,230,816
Qube Research & Technologies Ltd	1.3%	1,186,507	-42%	0.01%	$8,578,446
NORTHERN TRUST CORP	1.2%	1,135,565	+18%	0%	$8,210,134
FEDERATED HERMES, INC.	1.2%	1,129,538	+0.64%	0.01%	$8,166,560
Point72 Asset Management, L.P.	1.2%	1,073,963	+100%	0.02%	$7,764,751
ALGERT GLOBAL LLC	0.98%	913,065		0.11%	$6,601,000
ACADIAN ASSET MANAGEMENT LLC	0.87%	810,512	-16%	0.01%	$5,856,000
HRT FINANCIAL LP	0.85%	790,569	+465%	0.02%	$5,715,000
TWO SIGMA INVESTMENTS, LP	0.78%	728,674	+34%	0.01%	$5,268,313
Nuveen, LLC	0.78%	724,896	-1.9%	0%	$5,240,999

Institutional Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q4	1,617,330	$9,954,909	-$1,023,488			615.02%	8
2025 Q3	88,546,250	$640,111,586	+$7,175,915	$136,647	$622,603	723%	214
2025 Q2	90,531,530	$480,772,771	-$73,903,605	$75,402	$2,443,062	531%	217
2025 Q1	93,969,029	$833,362,458	+$10,158,317	$161,434	$846,198	887%	226
2024 Q4	92,372,582	$1,266,957,039	-$38,645,269	$283,797	$4,067,757	1,371%	215
2024 Q3	90,691,605	$2,483,201,978	-$46,950,016	$931,260	$2,741,739	2,739%	242
2024 Q2	92,275,241	$2,256,905,267	-$38,833,250	$2,773,764	$2,852,036	2,446%	222
2024 Q1	93,842,572	$2,001,184,734	+$66,089,493	$304,876	$5,973,864	2,132%	185
2023 Q4	65,732	$1,258,111	-$1,372,070			1,914%	2
2023 Q3	82,691,376	$1,326,371,004	+$18,568,848	$256,640	$5,686,180	1,604%	182
2023 Q2	81,069,871	$1,879,159,963	-$25,379,277	$424,194	$15,243,168	2,318%	183
2023 Q1	82,216,167	$1,909,846,504	+$45,557,038	$69,690	$15,357,461	2,323%	186
2022 Q4	80,349,837	$1,165,822,560	-$18,102,679	$40,628	$976,523	1,451%	188
2022 Q3	81,339,844	$1,552,155,021	+$29,736,892	$832,000	$2,242,000	1,908.03%	180
2022 Q2	79,886,468	$1,448,859,662	+$16,615,174	$887,000	$4,269,000	1,817.01%	183
2022 Q1	78,868,034	$1,987,215,536	+$13,546,984	$789,000	$6,996,000	2,520%	198
2021 Q4	78,260,576	$2,159,040,726	-$42,003,259	$2,230,000	$10,664,000	2,759.99%	189
2021 Q3	79,267,912	$2,560,527,030	+$118,586,402	$3,953,000	$7,204,000	3,229.01%	208
2021 Q2	75,479,987	$2,308,620,173	+$49,353,328	$2,616,000	$3,937,000	3,057.99%	199
2021 Q1	73,859,703	$2,248,584,947	-$33,447,138	$2,539,000	$3,739,000	3,044.96%	194
2020 Q4	74,793,856	$1,478,996,849	+$41,035,578	$2,837,000	$3,422,000	1,977.5%	174
2020 Q3	77,388,373	$1,009,274,628	+$16,361,222	$1,606,000	$1,834,000	1,303.99%	180
2020 Q2	72,867,201	$826,240,154	-$37,182,012	$2,441,000	$2,527,000	1,134%	185
2020 Q1	72,340,160	$1,035,278,531	-$106,690,504	$5,539,000	$2,473,000	1,431%	178
2019 Q4	78,565,203	$2,139,263,008	+$33,195,824	$12,838,000	$8,625,000	2,723%	213
2019 Q3	77,291,399	$2,213,387,805	+$28,928,482	$12,929,000	$9,939,000	2,863%	213
2019 Q2	76,580,415	$2,126,620,475	-$35,485,605	$23,094,000	$18,806,000	2,778%	227
2019 Q1	78,404,880	$2,603,655,899	+$91,721,730	$52,643,000	$21,387,000	3,320%	254
2018 Q4	75,763,137	$2,201,774,533	+$4,437,682	$5,136,000	$2,257,000	2,906.97%	254
2018 Q3	75,185,078	$3,458,603,828	+$104,340,457	$13,005,000	$9,449,000	4,600%	274
2018 Q2	73,211,328	$2,736,327,105	-$3,852,858	$6,135,000	$8,584,000	3,736.98%	244
2018 Q1	74,750,912	$2,208,281,826	+$13,556,402	$6,969,000	$10,688,000	2,955%	248
2017 Q4	74,563,674	$2,560,976,780	-$23,554,026	$5,237,000	$7,368,000	3,434.49%	240
2017 Q3	74,426,721	$2,692,530,693	-$243,357,111	$17,613,000	$9,144,000	3,617.99%	210
2017 Q2	81,771,576	$2,112,752,010	-$23,713,963	$13,283,000	$18,206,000	2,583.98%	232
2017 Q1	83,409,024	$1,601,328,626	+$190,628,749	$8,259,000	$3,930,000	1,920%	229
2016 Q4	79,796,561	$1,330,583,231	-$62,889,052	$19,055,000	$3,936,000	1,666.98%	217
2016 Q3	82,688,844	$1,701,064,840	-$42,443,358	$7,564,000	$4,835,000	2,058.01%	217
2016 Q2	81,092,174	$2,481,784,291	-$38,582,394	$24,683,000	$7,387,000	3,060%	250
2016 Q1	81,714,796	$3,058,390,588	-$306,379,847	$7,846,000	$3,513,000	3,743%	226
2015 Q4	89,647,685	$3,869,748,353	-$59,111,988	$11,073,000	$7,404,000	4,316.01%	226
2015 Q3	90,368,646	$3,386,916,178	-$73,220,551	$26,202,000	$26,399,000	3,748%	228
2015 Q2	92,250,312	$3,135,517,683	-$20,816,239	$14,961,000	$8,782,000	3,398.98%	231
2015 Q1	92,602,268	$3,277,634,496	-$49,807,145	$19,049,000	$18,294,000	3,539.99%	250
2014 Q4	93,540,279	$3,187,572,704	-$76,123,997	$45,161,000	$17,195,000	3,405.99%	262
2014 Q3	95,413,931	$3,679,966,481	-$223,340,928	$39,120,000	$31,072,000	3,857%	269
2014 Q2	100,966,204	$3,929,478,425	-$204,407,756	$113,350,000	$31,391,000	3,892%	279
2014 Q1	107,564,488	$3,683,154,847	+$240,568,829	$140,110,000	$49,717,000	3,418.98%	274